我們已在上線!
進一步了解
BLU
BELLUS Health Inc.
BLU
BLU
已下市
BLU已於2023年6月28日下市。
關於: BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.
員工: 74
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於BLU的最新新聞文章。
價格圖表採用Lightweight Charts™實作